Seojeong Park

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Structure-function analysis of access engineering in an FMNH2-dependent monooxygenase for enhanced polyethylene surface oxidation.

Structure-function analysis of access engineering in an FMNH2-dependent monooxygenase for enhanced polyethylene surface oxidation.

Journal: International journal of biological macromolecules

Published: May 07, 2026

Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation.

Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 19, 2025

Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction.

Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction.

Journal: eLife

Published: December 06, 2024

Computer-aided discovery of novel AMPK activators through virtual screening and SAR-driven synthesis.

Computer-aided discovery of novel AMPK activators through virtual screening and SAR-driven synthesis.

Journal: European journal of medicinal chemistry

Published: November 13, 2024

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer.

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer.

Journal: Molecular cancer

Published: October 19, 2024

Calpain 2 Isoform-Specific Cleavage of Filamin A Enhances HIF1α Nuclear Translocation, Promoting Metastasis in Triple-Negative Breast Cancer.

Calpain 2 Isoform-Specific Cleavage of Filamin A Enhances HIF1α Nuclear Translocation, Promoting Metastasis in Triple-Negative Breast Cancer.

Journal: MedComm

Published: July 30, 2024

Exploring novel A2AAR antagonists: Design, synthesis, and evaluation of 2,6,9-trisubstituted purine derivatives as promising antifibrotic agents.

Exploring novel A2AAR antagonists: Design, synthesis, and evaluation of 2,6,9-trisubstituted purine derivatives as promising antifibrotic agents.

Journal: Bioorganic & medicinal chemistry

Published: June 24, 2024

Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy.

Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy.

Journal: ACS nano

Published: January 30, 2024

A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model.

A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model.

Journal: International journal of biological sciences

Published: November 18, 2023

Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.

Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.

Journal: Bioorganic & medicinal chemistry

Published: May 01, 2023

Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.

Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.

Journal: European journal of medicinal chemistry

Published: November 21, 2022

Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Journal: Journal of medicinal chemistry

Published: July 07, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026